Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ficorella

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
From adjuvant to preventive breast cancer treatment: bridging the gap over troubled watersE Ricevuto, Z C Di Rocco, T Sidoni, et al.
The Mount Sinai Journal of Medicine, New York|June 1, 1985
Colorectal cancer (Duke's group B2, C1, C2): adjuvant chemotherapy and toxicityU Caruso, M Elli, E Cravotto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2004
Reducing breast cancer incidence in familial breast cancer: overlooking the present panoramaP Marchetti, C Z Di Rocco, E Ricevuto, et al.
British Journal of Cancer|May 29, 2003
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicityG Cianci, M F Morelli, K Cannita, et al.
The American Journal of Pathology|February 1, 1996
Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparationE Ricevuto, C Ficorella, C Fusco, et al.
Minerva Medica|March 17, 2000
[The adjuvant therapy of colonic carcinoma in old age]C Ficorella, K Cannita, E Ricevuto, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 24, 2019
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancerB Ricciuti, M Brambilla, A Cortellini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Novel P53 mutations detected by FAMA in colorectal cancersF De Galitiis, K Cannita, A Tessitore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2007
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancerC Natoli, E Cianchetti, N Tinari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Prognostic value of p53 molecular status in high-risk primary breast cancerP Marchetti, K Cannita, E Ricevuto, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
From adjuvant to preventive breast cancer treatment: bridging the gap over troubled watersE Ricevuto, Z C Di Rocco, T Sidoni, et al.
The Mount Sinai Journal of Medicine, New York|June 1, 1985
Colorectal cancer (Duke's group B2, C1, C2): adjuvant chemotherapy and toxicityU Caruso, M Elli, E Cravotto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2004
Reducing breast cancer incidence in familial breast cancer: overlooking the present panoramaP Marchetti, C Z Di Rocco, E Ricevuto, et al.
British Journal of Cancer|May 29, 2003
Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicityG Cianci, M F Morelli, K Cannita, et al.
The American Journal of Pathology|February 1, 1996
Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparationE Ricevuto, C Ficorella, C Fusco, et al.
Minerva Medica|March 17, 2000
[The adjuvant therapy of colonic carcinoma in old age]C Ficorella, K Cannita, E Ricevuto, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 24, 2019
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancerB Ricciuti, M Brambilla, A Cortellini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 9, 2006
Novel P53 mutations detected by FAMA in colorectal cancersF De Galitiis, K Cannita, A Tessitore, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 21, 2007
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancerC Natoli, E Cianchetti, N Tinari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Prognostic value of p53 molecular status in high-risk primary breast cancerP Marchetti, K Cannita, E Ricevuto, et al.
Pageof 6